Comparison of Neurological and Functional outcomes after Administration of Granulocyte-Colony-Stimulating Factor in Motor-Complete versus Motor-Incomplete Postrehabilitated, Chronic Spinal Cord Injuries: A Phase I/II Study

Granulocyte-colony-stimulating factor (G-CSF) is a major growth factor in the activation and differentiation of granulocytes. This cytokine has been widely and safely employed in different disease conditions over many years. The administration of the growth factors in spinal cord injury (SCI) has be...

Full description

Bibliographic Details
Main Authors: Hooshang Saberi M.D., M.P.H., Nazi Derakhshanrad, Mir Saeed Yekaninejad
Format: Article
Language:English
Published: SAGE Publishing 2014-01-01
Series:Cell Transplantation
Online Access:https://doi.org/10.3727/096368914X684943
id doaj-9131a62c156e43f598b62efbb2a69be6
record_format Article
spelling doaj-9131a62c156e43f598b62efbb2a69be62020-11-25T03:15:33ZengSAGE PublishingCell Transplantation0963-68971555-38922014-01-012310.3727/096368914X684943Comparison of Neurological and Functional outcomes after Administration of Granulocyte-Colony-Stimulating Factor in Motor-Complete versus Motor-Incomplete Postrehabilitated, Chronic Spinal Cord Injuries: A Phase I/II StudyHooshang Saberi M.D., M.P.H.0Nazi Derakhshanrad1Mir Saeed Yekaninejad2Department of Neurosurgery, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, IranBrain and Spinal Injuries Research Center (BASIR), Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, IranDepartment of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, IranGranulocyte-colony-stimulating factor (G-CSF) is a major growth factor in the activation and differentiation of granulocytes. This cytokine has been widely and safely employed in different disease conditions over many years. The administration of the growth factors in spinal cord injury (SCI) has been reported elsewhere; here we have tried to see the effect of SCI severity on the neurological outcomes after neuroprotective treatment for SCI with G-CSF. Seventy-four consecutive patients with SCI of at least 6 months' duration, with stable neurological status in the last 3 months, having informed consent for the treatment were included in the study. All the patients had undergone at least 3 months of standard rehabilitation. Patients were assessed by the American Spinal Injury Association (ASIA) scale, Spinal Cord Independence Measure (SCIM) III, and International Association of Neurorestoratology-Spinal Cord Injury Functional Rating Scale (IANR-SCIFRS) just before intervention and periodically until 6 months after subcutaneous administration of 5 μg/kg per day of G-CSF for 7 consecutive days. Multiple linear regression models were performed for statistical evaluation of lesion completeness and level of injury on changes in ASIA motor, light touch, pinprick, IANR-SCIFRS, and SCIM III scores, as a phase I/II comparative study. The study consisted of 52 motor-complete and 22 motor-incomplete SCI patients. There was no significant difference regarding age and sex, chronicity, and level of SCI between the two groups. Motor-incomplete patients had significantly more improvement in ASIA motor score compared to the motor-complete patients (7.68 scores, p < 0.001); also they had significant improvement in light touch (6.42 scores, p = 0.003) and pinprick sensory scores (4.89 scores, p = 0.011). Therefore, G-CSF administration in motor-incomplete SCIs is associated with significantly higher motor improvement, and also the higher the initial ASIA Impairment Scale (AIS) grade, the less would be the final AIS change, and incomplete cases are more welcome into the future studies. This manuscript is published as part of the International Association of Neurorestoratology (IANR) special issue of Cell Transplantation .https://doi.org/10.3727/096368914X684943
collection DOAJ
language English
format Article
sources DOAJ
author Hooshang Saberi M.D., M.P.H.
Nazi Derakhshanrad
Mir Saeed Yekaninejad
spellingShingle Hooshang Saberi M.D., M.P.H.
Nazi Derakhshanrad
Mir Saeed Yekaninejad
Comparison of Neurological and Functional outcomes after Administration of Granulocyte-Colony-Stimulating Factor in Motor-Complete versus Motor-Incomplete Postrehabilitated, Chronic Spinal Cord Injuries: A Phase I/II Study
Cell Transplantation
author_facet Hooshang Saberi M.D., M.P.H.
Nazi Derakhshanrad
Mir Saeed Yekaninejad
author_sort Hooshang Saberi M.D., M.P.H.
title Comparison of Neurological and Functional outcomes after Administration of Granulocyte-Colony-Stimulating Factor in Motor-Complete versus Motor-Incomplete Postrehabilitated, Chronic Spinal Cord Injuries: A Phase I/II Study
title_short Comparison of Neurological and Functional outcomes after Administration of Granulocyte-Colony-Stimulating Factor in Motor-Complete versus Motor-Incomplete Postrehabilitated, Chronic Spinal Cord Injuries: A Phase I/II Study
title_full Comparison of Neurological and Functional outcomes after Administration of Granulocyte-Colony-Stimulating Factor in Motor-Complete versus Motor-Incomplete Postrehabilitated, Chronic Spinal Cord Injuries: A Phase I/II Study
title_fullStr Comparison of Neurological and Functional outcomes after Administration of Granulocyte-Colony-Stimulating Factor in Motor-Complete versus Motor-Incomplete Postrehabilitated, Chronic Spinal Cord Injuries: A Phase I/II Study
title_full_unstemmed Comparison of Neurological and Functional outcomes after Administration of Granulocyte-Colony-Stimulating Factor in Motor-Complete versus Motor-Incomplete Postrehabilitated, Chronic Spinal Cord Injuries: A Phase I/II Study
title_sort comparison of neurological and functional outcomes after administration of granulocyte-colony-stimulating factor in motor-complete versus motor-incomplete postrehabilitated, chronic spinal cord injuries: a phase i/ii study
publisher SAGE Publishing
series Cell Transplantation
issn 0963-6897
1555-3892
publishDate 2014-01-01
description Granulocyte-colony-stimulating factor (G-CSF) is a major growth factor in the activation and differentiation of granulocytes. This cytokine has been widely and safely employed in different disease conditions over many years. The administration of the growth factors in spinal cord injury (SCI) has been reported elsewhere; here we have tried to see the effect of SCI severity on the neurological outcomes after neuroprotective treatment for SCI with G-CSF. Seventy-four consecutive patients with SCI of at least 6 months' duration, with stable neurological status in the last 3 months, having informed consent for the treatment were included in the study. All the patients had undergone at least 3 months of standard rehabilitation. Patients were assessed by the American Spinal Injury Association (ASIA) scale, Spinal Cord Independence Measure (SCIM) III, and International Association of Neurorestoratology-Spinal Cord Injury Functional Rating Scale (IANR-SCIFRS) just before intervention and periodically until 6 months after subcutaneous administration of 5 μg/kg per day of G-CSF for 7 consecutive days. Multiple linear regression models were performed for statistical evaluation of lesion completeness and level of injury on changes in ASIA motor, light touch, pinprick, IANR-SCIFRS, and SCIM III scores, as a phase I/II comparative study. The study consisted of 52 motor-complete and 22 motor-incomplete SCI patients. There was no significant difference regarding age and sex, chronicity, and level of SCI between the two groups. Motor-incomplete patients had significantly more improvement in ASIA motor score compared to the motor-complete patients (7.68 scores, p < 0.001); also they had significant improvement in light touch (6.42 scores, p = 0.003) and pinprick sensory scores (4.89 scores, p = 0.011). Therefore, G-CSF administration in motor-incomplete SCIs is associated with significantly higher motor improvement, and also the higher the initial ASIA Impairment Scale (AIS) grade, the less would be the final AIS change, and incomplete cases are more welcome into the future studies. This manuscript is published as part of the International Association of Neurorestoratology (IANR) special issue of Cell Transplantation .
url https://doi.org/10.3727/096368914X684943
work_keys_str_mv AT hooshangsaberimdmph comparisonofneurologicalandfunctionaloutcomesafteradministrationofgranulocytecolonystimulatingfactorinmotorcompleteversusmotorincompletepostrehabilitatedchronicspinalcordinjuriesaphaseiiistudy
AT naziderakhshanrad comparisonofneurologicalandfunctionaloutcomesafteradministrationofgranulocytecolonystimulatingfactorinmotorcompleteversusmotorincompletepostrehabilitatedchronicspinalcordinjuriesaphaseiiistudy
AT mirsaeedyekaninejad comparisonofneurologicalandfunctionaloutcomesafteradministrationofgranulocytecolonystimulatingfactorinmotorcompleteversusmotorincompletepostrehabilitatedchronicspinalcordinjuriesaphaseiiistudy
_version_ 1724638843080015872